Revelation Biosciences (REVB) Expected to Announce Earnings on Friday

Revelation Biosciences (NASDAQ:REVB) is anticipated to announce its results before the market opens on Friday, November 14th. Analysts expect the company to announce earnings of ($1.34) per share for the quarter.

Revelation Biosciences (NASDAQ:REVB) last released its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.43). On average, analysts expect Revelation Biosciences to post $-49 EPS for the current fiscal year and $-34 EPS for the next fiscal year.

Revelation Biosciences Stock Performance

Shares of REVB opened at $0.98 on Thursday. Revelation Biosciences has a 1 year low of $0.96 and a 1 year high of $60.48. The stock has a market capitalization of $15.12 million, a PE ratio of -0.03 and a beta of -0.11. The stock has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $3.16.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Revelation Biosciences in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Revelation Biosciences presently has a consensus rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.